Identification and characterization of a novel SNAT2 (SLC38A2) inhibitor reveals synergy with glucose transport inhibition in cancer cells

• Egile Nagusiak: Gregory Gauthier-Coles (Egilea), Angelika Bröer (Egilea), Malcolm Donald McLeod (Egilea), Amee J. George (Egilea), Ross D. Hannan (Egilea), Stefan Bröer (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

SNAT2 (SLC38A2) is a sodium-dependent neutral amino acid transporter, which is important for the accumulation of amino acids as nutrients, the maintenance of cellular osmolarity, and the activation of mTORC1. It also provides net glutamine for glutaminolysis and consequently presents as a potential...